Posted by Michael Wonder on 31 May 2022
argenx announces the UK MHRA has granted early access to efgartigimod for generalised myasthenia gravis
31 May 2022 - Efgartigimod was granted a promising innovative medicine designation by UK’s MHRA in November 2021.
argenx today announced that efgartigimod, the Company’s neonatal Fc receptor blocker, has been awarded a positive scientific opinion by the MHRA under the Early Access to Medicines Scheme.
